Our prescribing pharmacist can assess your eligibility and prescribe Ozempic, Wegovy, or Mounjaro — no doctor’s referral, no GP wait list. The consultation is covered by Alberta Health Care.
Who qualifies: BMI ≥ 30, or BMI ≥ 27 with a weight-related health condition
GLP-1 stands for glucagon-like peptide-1 — a hormone your gut naturally produces after eating. It signals your brain that you’re full, slows gastric emptying, and reduces appetite. In people with obesity, this signal is often blunted or dysregulated.
GLP-1 receptor agonist medications mimic and amplify this hormone at pharmacological doses. The result is a significant and sustained reduction in appetite, slower digestion, and meaningful weight loss — without the stimulant effects or cardiovascular risks associated with older weight loss drugs.
These are not appetite suppressants in the traditional sense. They work by correcting a hormonal dysregulation, which is why weight regain after stopping the medication is common. Your pharmacist will discuss what a sustainable, long-term approach looks like for your situation.
GLP-1 medications are once-weekly subcutaneous injections administered using a pre-filled pen. Most patients are comfortable self-administering after a brief pharmacist demonstration.
Our pharmacist can prescribe and dispense all three of the leading GLP-1 weight management medications. Availability is subject to current supply.
Semaglutide 0.5 mg / 1 mg / 2 mg
Ozempic is a weekly semaglutide injection approved by Health Canada for Type 2 diabetes management and widely prescribed off-label for weight loss. It was the drug that brought GLP-1 therapy into mainstream awareness in Canada.
The medication is titrated gradually — starting at 0.25 mg weekly and increasing over 4–8 months — to reduce gastrointestinal side effects and maximise tolerability.
Semaglutide 2.4 mg
Wegovy is Health Canada–approved specifically for chronic weight management in adults with obesity or overweight with a comorbidity. It uses the same active ingredient as Ozempic but at a higher maintenance dose (2.4 mg weekly), producing greater average weight loss.
The dedicated obesity indication means it may be more straightforward to obtain private drug plan coverage compared to off-label use of Ozempic.
Tirzepatide 2.5 mg → 15 mg
Mounjaro (tirzepatide) is a dual agonist — it activates both GLP-1 and GIP receptors, two complementary appetite and metabolism pathways. Clinical trials show it produces greater average weight loss than semaglutide. It is Health Canada–approved for Type 2 diabetes.
For patients who have not responded adequately to semaglutide, or who want the strongest evidence-based option available, tirzepatide may be a clinically appropriate alternative.
Under Alberta’s pharmacist prescribing regulations, pharmacists with additional prescribing authorization (APA) can independently assess patients and prescribe medications including GLP-1 agents for weight management. This is not a pilot program or a referral pathway — it is full independent prescribing authority.
The assessment covers your medical history, current medications, relevant lab values (where available), and clinical eligibility. If you are appropriate for GLP-1 therapy, the pharmacist writes the prescription and it can be filled at the same counter during the same visit.
Your pharmacist will review your BMI, weight history, and any existing health conditions. They assess for contraindications (including personal or family history of medullary thyroid carcinoma, pancreatitis, or MEN2 syndrome), check your current medications for interactions, and establish a baseline before initiating therapy.
The consultation itself is covered by Alberta Health Care. Bring your Alberta Health Card. The cost of the medication is a separate discussion.
A GLP-1 program is not a one-time prescription. Your pharmacist schedules follow-up check-ins to review tolerability, manage any side effects (nausea, constipation, injection site reactions), and guide dose titration over time. You have access to your prescribing pharmacist for questions throughout the program — something a telehealth prescription service cannot provide.
Final eligibility is determined at the pharmacist assessment. If you don’t meet criteria, your pharmacist will explain why and discuss alternative options.
GLP-1 therapy requires gradual dose titration. Here is what most patients experience during the first 12 weeks.
You begin at the lowest starting dose (0.25 mg for semaglutide, 2.5 mg for tirzepatide). This period is primarily about tolerability. Most patients experience some degree of nausea, reduced appetite, or mild fatigue as the body adjusts.
Weight loss at this stage is modest — typically 1–3 kg. The primary goal is establishing that you can tolerate the medication before dose escalation.
The dose is increased every 4 weeks as tolerated. Appetite suppression becomes more pronounced. Most patients report significantly reduced hunger, fewer cravings, and a natural reduction in portion sizes without effort.
Weight loss accelerates. Clinical studies show an average of 5–8% of body weight loss by week 12 at therapeutic doses.
At your 3-month review, your pharmacist documents your weight loss, reviews tolerability at the current dose, and discusses the next phase of your program. This is also when drug plan coverage renewals and prior authorization paperwork are typically addressed.
Patients who have lost ≥ 5% of body weight at 12 weeks are considered responders and benefit significantly from continuing therapy. Those who have not responded are reassessed to determine whether dose adjustment, a medication switch, or additional support is appropriate.
Costs vary depending on which medication, your drug benefit plan, and whether you qualify for coverage. Here is a realistic breakdown.
Your initial assessment and follow-up pharmacist consultations are covered by Alberta Health Care. Bring your Alberta Health Card.
This includes the full eligibility assessment, prescription writing, initial dispensing counselling, and scheduled follow-up check-ins throughout your program.
Book Your AssessmentMany employer benefit plans (Sun Life, Manulife, Great-West Life, Canada Life) cover Wegovy and Ozempic for weight management. Coverage often requires a prior authorization form completed by your prescriber. Our pharmacist can complete this paperwork.
Provincial plans (AHCIP drug benefit, AISH, seniors) generally do not cover GLP-1 medications for obesity without a concurrent Type 2 diabetes diagnosis. If you have Type 2 diabetes, coverage for Ozempic as a diabetes medication is often available.
Without coverage, Ozempic and Wegovy typically cost $250–$400/month at standard doses. Mounjaro is similar in range. Manufacturer patient assistance programs (Novo Nordisk, Eli Lilly) are available for some patients. Ask our pharmacist for current pricing.
How does starting your GLP-1 program through Acme Drug Mart compare to other common pathways in Edmonton?
| Factor | GP Wait List | Weight Loss Clinic | Acme Drug Mart Pharmacist |
|---|---|---|---|
| Wait time to first appointment | Weeks to months (GP shortage) | Days to 2 weeks; often fee-based | Walk in — same day |
| Referral required | None, but limited availability | Self-referral; may need GP for labs | No referral required |
| Consultation cost | Covered by AHC | Often $150–$300 for initial visit | Covered by AHC |
| Prescription & dispensing | Prescription only; fill elsewhere | May or may not dispense on site | Prescribed and dispensed same visit |
| Ongoing support & monitoring | GP follow-up (hard to book) | Structured follow-up; additional fees | Built-in pharmacist follow-up; AHC-covered |
| Prior authorization paperwork | GP completes; scheduling required | Clinic completes; included in fees | Pharmacist completes; no extra charge |
Answers to the questions we hear most often about GLP-1 weight loss programs in Edmonton.
Yes. Under Alberta’s pharmacist prescribing regulations, a pharmacist with additional prescribing authorization (APA) can independently assess eligibility and prescribe GLP-1 medications including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) for weight management.
No GP referral is required. The pharmacist consultation is covered by Alberta Health Care.
The pharmacist consultation is covered by Alberta Health Care. The GLP-1 medications themselves are generally not covered by provincial drug benefit plans for obesity without a concurrent Type 2 diabetes diagnosis.
However, many private employer drug benefit plans (Sun Life, Manulife, Great-West Life, Canada Life) do cover Wegovy and Ozempic for weight management. Our pharmacist can help you understand your specific coverage situation and complete any required prior authorization forms.
Both contain the same active ingredient — semaglutide — but they are approved for different purposes and come in different dose ranges.
Ozempic is Health Canada–approved for Type 2 diabetes management and is widely prescribed off-label for weight loss at doses up to 2 mg weekly.
Wegovy is specifically Health Canada–approved for chronic weight management in adults with obesity or overweight with a comorbidity. It reaches a higher maintenance dose (2.4 mg weekly), producing greater average weight loss in clinical trials. Wegovy may be easier to obtain drug plan coverage for, since it carries an obesity indication.
Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist — it activates two appetite-regulating pathways rather than one. GIP (glucose-dependent insulinotropic polypeptide) works synergistically with GLP-1 to further reduce appetite and improve metabolic function.
Clinical trials (the SURMOUNT program) show tirzepatide produces greater average weight loss than semaglutide alone — up to 22% of body weight at the highest dose. Mounjaro is Health Canada–approved for Type 2 diabetes. Our pharmacist can discuss whether tirzepatide is clinically appropriate for you.
Clinical eligibility for GLP-1 weight management typically requires:
BMI of 30 or higher (obesity), regardless of other health conditions, or
BMI of 27 or higher (overweight) with at least one weight-related comorbidity such as Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.
Additional factors including medical history, current medications, kidney function, and contraindications are reviewed during the pharmacist assessment. Final eligibility is determined at the consultation.
No. Our prescribing pharmacist can independently assess your eligibility and, if appropriate, prescribe and dispense a GLP-1 medication during a single visit. You do not need a GP referral, a specialist appointment, or a prior diagnosis of any condition.
Walk in to Acme Drug Mart or call (780) 443-0202 to get started.
Most patients begin noticing reduced appetite within the first 1–2 weeks. Meaningful weight loss typically begins within the first 4–8 weeks, with the greatest effects accumulating over 6–12 months as the dose is titrated upward.
Clinical studies show an average of 5–8% body weight reduction at 12 weeks and 15–22% at 12–18 months depending on the medication. Individual results vary based on adherence, dietary changes, and baseline health.
Walk in or call Acme Drug Mart — (780) 443-0202. No referral, no wait list. Consultation covered by Alberta Health Care.